Michael A Kahn

US Patent:

8293743, Oct 23, 2012

Filed:

Nov 11, 2009

Appl. No.:

12/616712

Inventors:

Michael Kahn - Los Angeles CA, US

Assignee:

Choongwae Pharma Corporation - Seoul

International Classification:

A61K 31/495

US Classification:

514249, 544349

Abstract:

The invention provides α-mimetic structures represented by Formula (VI) and a chemical library relating thereto. Additionally, the invention provides methods wherein α-mimetic compounds are used to treat cancer stem cells.

US Patent:

8604018, Dec 10, 2013

Filed:

Mar 28, 2011

Appl. No.:

13/073176

Inventors:

Michael Kahn - Altadena CA, US
Masakatsu Eguchi - Bellevue WA, US

Assignee:

Institute for Chemical Genomics - Altadena CA

International Classification:

A61K 31/553
A61K 31/554
A61K 31/519

US Classification:

51421109, 5142621

Abstract:

The invention provides α-helix mimetic structures and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis.

US Patent:

20070128669, Jun 7, 2007

Filed:

Nov 27, 2006

Appl. No.:

11/605202

Inventors:

Michael Kahn - Los Angeles CA, US

Assignee:

Institute for Chemical Genomics - Kirkland WA

International Classification:

G01N 33/567
G01N 33/53

US Classification:

435007200

Abstract:

Methods and agents are disclosed for modulating the interaction of β-catenin or γ-catenin with CBP or p300. Agents that increase the binding of CBP to β-catenin are associated with enhancing the β-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells, as well as embryonic stem cells.

US Patent:

20110039333, Feb 17, 2011

Filed:

Aug 12, 2010

Appl. No.:

12/855578

Inventors:

Michael Kahn - Altadena CA, US
Kouichi Hasegawa - Pasadena CA, US
Jia-Ling Teo - Altadena CA, US
Michael McMillan - Alhambra CA, US

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

International Classification:

C12N 5/0735

US Classification:

435366, 435404

Abstract:

The invention relates to human pluripotent cells. More specifically, the invention provides a chemically defined xeno-free culture system that allows for long term expansion of human pluripotent cells. This culture system allows for human pluripotent cell lines to be maintained in the pluripotent state for an extended time while maintaining a normal karyotype and the ability to differentiate into all three germ layers.

US Patent:

D3731685, Aug 27, 1996

Filed:

May 3, 1994

Appl. No.:

D/022258

Inventors:

Michael Kahn - Los Angeles CA

US Classification:

D21238

US Patent:

20220370874, Nov 24, 2022

Filed:

Aug 3, 2022

Appl. No.:

17/880301

Inventors:

- Los Angeles CA, US
Michael Kahn - Los Angeles CA, US

International Classification:

A63B 69/00
A63B 21/00
G09B 19/00
A63B 60/46
A63B 69/36
G16H 20/30
G06V 40/20

Abstract:

Described herein are devices and systems relating to sports training equipment, for example, for baseball. These devices and systems can comprise a mat with markers identifying a plurality of positions on the mat. In some embodiments, the system can comprise removably attachable footpads to identify ideal foot positions for an athletic performance. In some embodiments, the footpads comprise one or more pressure sensors. The system can comprise one or more position sensors on a ball, and one or more position sensors removably attachable to a hand-held sports instrument. In some embodiments, the system can comprise a memory, communicatively coupled to a processor and a camera, with executable instructions to implement a set-up component, a user recognition component, a practice component, and instructional component, and a play component.

US Patent:

20220354852, Nov 10, 2022

Filed:

May 9, 2022

Appl. No.:

17/662629

Inventors:

- Duarte CA, US
Michael KAHN - Duarte CA, US
Christine BROWN - Duarte CA, US

Assignee:

CITY OF HOPE - Duarte CA

International Classification:

A61K 31/519
A61P 35/00
A61K 35/17
A61K 38/17
A61K 31/675

Abstract:

This disclosure relates to cells that express a chimeric antigen receptor that targets IL13Rα2 and/or HER2 and methods for treating a brain tumor by administering a population of cells expressing a chimeric antigen receptor that targets IL13Rα2 and/or HER2 in combination with a Wnt/β-catenin pathway modulator to a subject having a brain tumor.

US Patent:

20190125753, May 2, 2019

Filed:

Apr 20, 2017

Appl. No.:

16/095290

Inventors:

- Los Angeles CA, US
Michael McMillan - Alhambra CA, US
Yusuke Higuchi - Los Angeles CA, US
Michael Kahn - Altadena CA, US
Cu D. Nguyen - Azusa CA, US

International Classification:

A61K 31/53
A61K 31/519
A61P 7/06

Abstract:

Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Ris hydrogen or C-Calkyl; ring A is cyclohexyl or phenyl, optionally substituted; ring B is aryl or a nitrogen-containing heteroaryl, optionally substituted; ring C is phenyl substituted with hydroxyl; each L, Land Lis independently C-Calkyl, —CONR— or —CONR—X—C-Calkyl-, each optionally substituted; Ris hydrogen or C-Calkyl; and X is a bond or a 5-6 membered heterocycle containing up to 3 ring heteroatoms; and methods of use such as a method for increasing hematopoiesis, for enhancing expansion of a hematopoietic stem cell (HSC), or for inhibiting an interaction between a β-, and/or γ-catenin protein in a cell or a subject by administering a compound of Formula (I) to the subject.